Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.26 USD
Change Today -0.24 / -9.60%
Volume 1.0M
As of 8:10 PM 06/29/15 All times are local (Market data is delayed by at least 15 minutes).

durect corporation (DRRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/8/15 - $3.42
52 Week Low
10/27/14 - $0.68
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DURECT CORPORATION (DRRX)

durect corporation (DRRX) Related Businessweek News

No Related Businessweek News Found

durect corporation (DRRX) Details

DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceuticals products based on its proprietary drug formulations and delivery platform technologies in the United States, Europe, Japan, and internationally. It provides ALZET product line comprising osmotic pumps and accessories that are used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers, which are used as raw materials for pharmaceutical and medical device under the LACTEL brand. It also focuses on developing products for various chronic and episodic, or acute medical conditions, including pain, central nervous system disorders, metabolic disorders, cardiovascular disease, ophthalmic disorders, and other diseases. The company develops REMOXY, an oral oxycodone gelatin capsule for chronic pain; POSIDUR, a formulation of bupivacaine for the treatment of post-surgical pain; ELADUR, a transdermal bupivacaine for the treatment of pain associated with post-herpetic neuralgia; and Relday, a risperidone product to treat the symptoms of schizophrenia and bipolar I disorder in adults and teenagers. It also develops ORADUR-ADHD, a drug candidate for the treatment of attention deficit hyperactivity disorder; ORADUR-based opioids, including hydrocodone and hydromorphone that are in Phase I clinical trials to treat chronic pain, and oxymorphone; and DUR-928, an endogenous small molecule for the treatment of acute organ injuries and metabolic/lipid disorders. The company has collaboration agreements with Santen Pharmaceutical Co., Ltd., Impax Laboratories, Inc., Zogenix, Inc., Pain Therapeutics, Inc., and Hospira, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.

103 Employees
Last Reported Date: 05/1/15
Founded in 1998

durect corporation (DRRX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $470.4K
Co-Founder, Chairman and Chief Scientific Off...
Total Annual Compensation: $277.5K
Chief Financial Officer
Total Annual Compensation: $322.1K
Senior Vice President of Operations and Corpo...
Total Annual Compensation: $275.8K
Executive Vice President of Pharmaceutical Sy...
Total Annual Compensation: $340.0K
Compensation as of Fiscal Year 2014.

durect corporation (DRRX) Key Developments

DURECT Corporation Announces Plans to Conduct A New POSIDUR Phase 3 Clinical Trial

DURECT Corporation announced that, based on feedback from the FDA, it plans to conduct a new POSIDUR Phase 3 clinical trial consisting of approximately 300 patients undergoing laparoscopic cholecystectomy (gallbladder removal) surgery. DURECT anticipates beginning the trial in the fall of 2015 and expects that it will take approximately one year to complete enrollment. The study will be a randomized, parallel-group, double-blind, placebo-controlled, multicenter trial of POSIDUR in patients undergoing laparoscopic cholecystectomy. The objective of the study will be to evaluate the safety and efficacy of POSIDUR for the management of postoperative pain. Approximately 300 patients will be randomized on a one-to-one basis to receive either POSIDUR or placebo as a one-time intra-incisional instillation at the close of surgery. The primary efficacy endpoint will be pain intensity on movement over 0-72 hours after surgery. Cholecystectomy is a surgical procedure for removal of the gallbladder. Laparoscopic cholecystectomy, which is done using a camera and instruments inserted through a set of small incisions in the abdomen, has largely supplanted the traditional open approach, which requires an abdominal incision several inches in length. Approximately 800,000 such procedures are performed in the U.S. each year, most of them on an outpatient basis. In a previous clinical trial consisting of 50 patients, when using the statistical analysis that will be employed in the upcoming trial, POSIDUR demonstrated an approximately 25% reduction in pain intensity on movement for the first 3 days after surgery (p=0.0235) when compared with the active control bupivacaine hydrochloride.

DURECT Announces Positive Results from DUR-928 Multi-Dose Phase 1 Study

DURECT Corporation announced that it has obtained positive results from a multi-dose Phase 1 clinical trial with an oral formulation of DUR-928, the lead molecule in DURECT's Epigenomic Regulator Program. DUR-928 is an endogenous, small-molecule, new chemical entity (NCE), which may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). It may also play an important role in protecting against acute kidney injury (AKI) and other types of acute organ injury.

DURECT Corporation Announces Information About Clinical Trials and its Plans for REMOXY

On May 11 and 12, 2015, DURECT Corporation's licensee for REMOXY, Pain Therapeutics Inc. (Pain Therapeutics), announced information about clinical trials and its plans for REMOXY, a novel long-acting oral formulation of the opioid oxycodone targeted to decrease the potential for oxycodone abuse. DURECT licensed development and commercialization rights to REMOXY to Pain Therapeutics, and Pain Therapeutics subsequently licensed these rights to King Pharmaceuticals Inc. (King). King was later acquired by Pfizer Inc. (Pfizer), and in October 2014, Pfizer informed Pain Therapeutics that it was returning its development and commercialization rights for REMOXY to Pain Therapeutics. Under the terms of DURECT's agreement with Pain Therapeutics, if REMOXY is commercialized, DURECT will receive royalties of between 6.0% to 11.5% of net sales depending on sales volumes.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DRRX:US $2.26 USD -0.24

DRRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Acura Pharmaceuticals Inc $0.94 USD +0.03
Egalet Corp $15.57 USD +0.50
Elite Pharmaceuticals Inc $0.20 USD -0.005
Veloxis Pharmaceuticals A/S kr0.87 DKK -0.03
Zogenix Inc $1.62 USD -0.05
View Industry Companies

Industry Analysis


Industry Average

Valuation DRRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.9x
Price/Book 19.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DURECT CORPORATION, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at